A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
A phase 3 trial of CAM2029 (octreotide subcutaneous depot) run by Camurus AB, active.
Overview
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET is a phase 3 interventional study registered as NCT05050942 by Camurus AB, with 332 participants enrolled, started 2021-10-22. Conditions listed: Gastro-enteropancreatic Neuroendocrine Tumor. No results are recorded here; the registry entry is the source.
Setting
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Phase
Phase 3
Sponsor
Camurus AB
Registry
Enrolled
332